Some pharmacokinetic data on miocamycin. I: Serum, urinary and prostatic levels.
The pharmacokinetics of miocamycin were studied in ten healthy male volunteers after three different administrations: the first group received 600 mg in a single oral dose; the second received 1200 mg divided into two administrations of 600 mg, each one every 12 h; the third received 1200 mg in a single oral dose. Prostatic levels of miocamycin were recorded after the administration of 1200 mg, divided into two administrations of 600 mg every 12 h. The pharmacokinetic analysis was carried out by applying a single-compartment kinetic model with zero-order absorption. The apparent duration of absorption (T) was about 0.55 h for all subjects. The area under the curve was 7.5767 +/- 0.2511 mg/h/l in the first group; 6.7333 +/- 0.6058 mg/h/l in the second group; and 18.6825 +/- 15.1555 mg/h/l in the third. The prostatic levels were five times higher than those in the serum at the same time.
Furneri
P M
PM
Institute of Microbiology, University of Catania, Italy.
Scalia
G
G
Garozzo
A
A
Tempera
G
G
D000293:Adolescent; D000328:Adult; D001770:Blood Bactericidal Activity; D006801:Humans; D007933:Leucomycins / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D008297:Male; D015644:Miocamycin; D009153:Mutagens / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine; D011467:Prostate / Q000378:metabolism*
D007933:Leucomycins; D009153:Mutagens; D015644:Miocamycin